Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.
Howles
Sarah
S
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.
Guimarães-Walker
Ana
A
Yang
Hongbing
H
Hancock
Gemma
G
di Gleria
Katalin
K
Tarragona-Fiol
Tony
T
Hayes
Peter
P
Gilmour
Jill
J
Bridgeman
Anne
A
Hanke
Tomáš
T
McMichael
Andrew
A
Dorrell
Lucy
L
D016915:AIDS Vaccines / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005822:Genetic Vectors; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D018023:HIV Seronegativity; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000276:immunology; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D055815:Young Adult
D016915:AIDS Vaccines; D018984:Epitopes, T-Lymphocyte; D007371:Interferon-gamma